Moderna (MRNA) PT Raised to $179 at Oppenheimer, 'mResvia is competitive as an RSV vaccine'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Moderna (MRNA) price target raised at Oppenheimer after RSV vaccine approval
June 12, 2024 7:45 AM EDTOppenheimer upped their price target on Moderna (NASDAQ: MRNA) after the US drugmaker recently saw its respiratory syncytial virus (RSV) vaccine, known as mRESVIA, approved by the Food and Drug Administration (FDA).
According to Oppenheimer, mResvia is entering the adult market (ages 60 and above), where it will... More
